Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Psoriasis - Pipeline Review, H2 2013 market report to its offering
Psoriasis - Pipeline Review, H2 2013
, 'Psoriasis - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. Psoriasis - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Psoriasis.
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Johnson & Johnson
Boehringer Ingelheim GmbH
Valeant Pharmaceuticals International
Antares Pharma, Inc.
Echo Therapeutics, Inc.
Stiefel Laboratories, Inc.
Piramal Healthcare Limited
Isotechnika Pharma Inc.
Dr. Reddy's Laboratories Limited
LEO Pharma A/S
Ono Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Sun Pharmaceutical Industries Limited
Can-Fite BioPharma Ltd.
Basilea Pharmaceutica Ltd.
Nuvo Research Inc.
Arena Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Cytos Biotechnology AG
Biotie Therapies Corp.
Provectus Pharmaceuticals, Inc.
Uni-Bio Science Group Ltd.
Synta Pharmaceuticals Corp.
Panacea Biotec Limited
Sareum Holdings plc
Advinus Therapeutics Pvt. Ltd.
Affimed Therapeutics AG
Jenrin Discovery, Inc.
Upsher-Smith Laboratories, Inc.
Palau Pharma S.A
Farmacija d.o.o. Tuzla
Acceleron Pharma, Inc.
Phenex Pharmaceuticals AG
Argos Therapeutics, Inc.
BioNumerik Pharmaceuticals, Inc.
Anacor Pharmaceuticals, Inc.
Coronado Biosciences, Inc.
Gene Signal International SA.
Catabasis Pharmaceuticals, Inc.
Orphagen Pharmaceuticals, Inc.
Ferrer Internacional S.A.
TcL Pharma SAS
Inimex Pharmaceuticals, Inc.
Sosei Co. Ltd.
Welichem Biotech Inc.
Redox Pharmaceutical Corporation
KaloBios Pharmaceuticals, Inc.
Kinex Pharmaceuticals, LLC
SWITCH Biotech LLC
KAHR medical Ltd.
Femta Pharmaceuticals, Inc.
Fibrocell Sciences, Inc.
Celtic Pharmaceutical Holdings L.P.
Laila Pharmaceuticals Pvt. Ltd.
To view the table of contents for this market research report please visit